WBUR News

Moderna says FDA refused its application for new mRNA flu vaccine

STAT

FDA refuses to review Modernas influenza vaccine

angie_rasmussen

drjohnm

j_g_allen

xray_media

cmyeaton

ramez

Investors

Moderna Stock Fda Cber Mrna Based Flu Shot

The New York Times

Fda Moderna Mrna Flu Vaccine.Html

Seeking Alpha

Moderna shares drop after FDA refuses to file for mRNA-1010 influenza vaccine (MRNA:NASDAQ)

The Wall Street Journal

Fda Refuses To Consider Approving Use Of Modernas New Flu Vaccine C1C6Ea42

FOX News

FDA refuses to review Modernas mRNA flu vaccine application

Moderna

News Release

FDA refuses to review Moderna’s application for mRNA flu vaccine, company says

Guardian

FDA declines to review Moderna application for new flu vaccine

Metaculus

Will a new tuberculosis vaccine be approved by the FDA, EMA, or PMDA before 2028?

Robert F. Kennedy Jr.

Bill Cassidy

Mehmet Oz

Jay Bhattacharya

Michael Osterholm

Jim O'Neill

Jason M. Goldman

Jesse L. Goodman

Kevin A. Ault

IDSA

Diana DeGette

Caitlin Rivers

Andrew Racine

Robert Goldstein

WLBT3

West Coast Health Alliance

Sean O'Leary

UC Berkeley School of Public Health

Marty Makary

"This decision protects children, respects families, and rebuilds trust in public health."

"This [2026] decision recommits HHS to all three [transparency, rigorous science, and respect for families]."

"This decision commits NIH, CDC, and FDA to gold standard science, greater transparency, and ongoing reassessment as new data emerge."

"No family will lose access.This [2026] framework empowers parents and physicians to make individualized decisions based on risk, while maintaining strong protection against serious disease."

"The data support a more focused schedule that protects children from the most serious infectious diseases while improving clarity, adherence, and public confidence."

“I think that a reduced schedule is going to endanger children and lay the groundwork for a resurgence in preventable disease.”

“Changing the pediatric vaccine schedule based on no scientific input on safety risks and little transparency will cause unnecessary fear for patients and doctors, and will make America sicker.”

"This wildly irresponsible decision will put lives at risk."

“There will be more diseases, more infection, more hospitalizations.”

Will Secretary Kennedy's U.S. Childhood Vaccine Schedule Overhaul Risk Public Health?

Moderna announced that the U.S. Food and Drug Administration issued a refusal-to-file letter regarding its application for an mRNA-based influenza vaccine, mRNA-1010. The FDA's Center for Biologics Evaluation and Research cited concerns about the trial design.

Moderna announced that the U.S. Food and Drug Administration issued a refusal-to-file letter regarding its application for an mRNA-based influenza vaccine, mRNA-1010. The FDA's Center for Biologics Evaluation and Research cited concerns about the trial design.

The FDA's letter, signed by Center Director Vinay Prasad, stated the trial lacked an adequate and well-controlled study because the comparator arm did not reflect the best-available standard of care. The letter did not identify any specific safety or efficacy concerns.

The FDA's letter, signed by Center Director Vinay Prasad, stated the trial lacked an adequate and well-controlled study because the comparator arm did not reflect the best-available standard of care. The letter did not identify any specific safety or efficacy concerns.

Moderna's Phase 3 trial compared its experimental vaccine against Fluarix Quadrivalent, a licensed standard-dose seasonal influenza vaccine sold by GSK, in a study of approximately 40,000 adults aged 50 and older. The trial concluded the new vaccine was more effective.

Moderna's Phase 3 trial compared its experimental vaccine against Fluarix Quadrivalent, a licensed standard-dose seasonal influenza vaccine sold by GSK, in a study of approximately 40,000 adults aged 50 and older. The trial concluded the new vaccine was more effective.

In April 2024, Moderna submitted its Phase 3 study protocol to the FDA for review, and the agency provided written guidance stating it would be acceptable to use a licensed standard-dose influenza vaccine as the comparator, though a vaccine for older adults was recommended.

In April 2024, Moderna submitted its Phase 3 study protocol to the FDA for review, and the agency provided written guidance stating it would be acceptable to use a licensed standard-dose influenza vaccine as the comparator, though a vaccine for older adults was recommended.

Moderna CEO Stéphane Bancel stated the FDA's decision does not further the shared goal of enhancing America's leadership in developing innovative medicines. The company has requested a meeting with the FDA to understand the path forward and noted the vaccine is under review in Europe.

Moderna CEO Stéphane Bancel stated the FDA's decision does not further the shared goal of enhancing America's leadership in developing innovative medicines. The company has requested a meeting with the FDA to understand the path forward and noted the vaccine is under review in Europe.

The decision comes amid increased scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., who has criticized mRNA technology. In 2025, Kennedy announced the cancellation of over $500 million in contracts and funding for mRNA vaccine development.

The decision comes amid increased scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., who has criticized mRNA technology. In 2025, Kennedy announced the cancellation of over $500 million in contracts and funding for mRNA vaccine development.

FDA Rejects Moderna's mRNA Flu Vaccine Over Trial Design

Moderna says FDA refusedRejects itsModerna's applicationmRNA forFlu newVaccine mRNAOver fluTrial vaccineDesign

The Controversies

Jr.

Makary

Bhattacharya

Oz

O'Neill

Rivers

Cassidy

Goodman

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters